Equity Overview
Price & Market Data
Price: $4.39
Daily Change: +$0.14 / 3.19%
Range: $4.30 - $4.39
Market Cap: $15,502,555
Volume: 701
Performance Metrics
1 Week: -1.85%
1 Month: 7.73%
3 Months: -15.51%
6 Months: -7.41%
1 Year: -59.71%
YTD: -13.79%
Company Details
Employees: 13
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company develops medications capable of once-daily dosing using its proprietary drug delivery platform technology, Precision Timed Release. Its drug candidates include CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD; CTx-1302 (dextroamphetamine), which is in Phase 1/2 clinical pharmacology and Phase 3 clinical trials for the treatment of ADHD in children; and CTx-2103 (buspirone) for the treatment of anxiety. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.